ZINC02092166|CAS 354543-09-2|DC Chemicals

Cas No.:	354543-09-2
Chemical Name:	4-amino-N'-{13-oxa-10,12,14,16-tetraazatetracyclo7.7.0.0^{2,7}.0^{11,15}hexadeca-1(16),2,4,6,9,11,14-heptaen-8-ylidene}-1,2,5-oxadiazole-3-carbohydrazide
Synonyms:	BDBM50094590;J3.583.511C;(E)-4-amino-N'-(9H-indeno[1,2-b][1,2,5]oxadiazolo[3,4-e]pyrazin-9-ylidene)-1,2,5-oxadiazole-3-carbohydrazide;(Z)-4-Amino-N'-(9H-indeno[1,2-b][1,2,5]oxadiazolo[3,4-e]pyrazin-9-ylidene)-1,2,5-oxadiazole-3-carbohydrazide;4-Amino-N'-(9H-indeno[1,2-b][1,2,5]oxadiazolo[3,4-e]pyrazin-9-ylidene)-1,2,5-oxadiazole-3-carbohydrazide;4-Amino-N'-[(9Z)-;Nc1nonc1C(=O)N\N=C1\c2ccccc2-c2nc3nonc3nc12;LQZ-7F;4-amino-N'-{13-oxa-10,12,14,16-tetraazatetracyclo7.7.0.0^{2,7}.0^{11,15}hexadeca-1(16),2,4,6,9,11,14-heptaen-8-ylidene}-1,2,5-oxadiazole-3-carbohydrazide
SMILES:	O1N=C2C(N1)=NC1=C(C3C=CC=CC=3C1=N2)/N=N/C(C1C(N)=NON=1)=O
Formula:	C₁₄H₇N₉O₃
M.Wt:	349.26388001442
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	1. Catrow JL, et al. J Med Chem. 2015 Jun 11;58(11):4678-92.

Description:	ZINC02092166 is a novel potent, and selective small-molecule inhibitor for the β-catenin/Tcf4 protein-protein interaction with Ki of 1.7 and 7.0 uM in AlphaScreen and FP assay (wild-type β-catenin), respectively; remain affinity for muant catenin V511S, V511S/I569S and R469A with Ki of 20-50 uM; exhibits dual selectivity for β-catenin/Tcf over β-catenin/cadherin and β-catenin/APC PPIs.
References:	1. Catrow JL, et al. J Med Chem. 2015 Jun 11;58(11):4678-92.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.